Please assess the completion status of the following clinical trial:

Trial Title: Pharmacological Penile Rehabilitation in the Preservation of Erectile Function Following Bilateral Nerve-Sparing Radical Prostatectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male, must be ≥ 18 years of age, with histologically confirmed prostate adenocarcinoma, that is clinically localized to the prostate gland~* Stable sexual relationship for ≥ 6 months~* Open or laparoscopic bilateral nerve-sparing radical prostatectomy~* Baseline score of ≥ 22 on the International Index of Erectile Function Domain (Appendix A)~* Able to speak, read and write in the English language~* Calculated creatinine clearance using the 4 variable MDRD equation based on serum creatinine, age, race, and gender of \> 60 cc/min~* Patient is able to walk up two flights of stairs briskly without chest pain~* Patient needs to have their baseline sitting AND standing blood pressure and pulse done at the time of consent~Exclusion Criteria:~* Preoperative or planned postoperative pelvic radiation therapy~* Preoperative or planned postoperative androgen deprivation~* Presence of Peyronie's disease at baseline~* Presence of a penile prosthesis at baseline~* Resection of one or both nerve bundles at surgery~* Any contraindications to sildenafil:~  * Patient is currently using nitrates;~ * Presence of retinitis pigmentosa;~ * Presence macular degeneration;~ * MI or CVA within 3 months;~ * Patient is currently using MAOI medications~* Patient is currently using penile self injection medication (Trimix, Bimix, or PGE-1)~* Patient requiring sildenafil for penetration~* Use of sildenafil within 30 days of consent

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PRN Sildenafil (Type: EXPERIMENTAL): Placebo QHS (blinded) and sildenafil 100mgs (open-label) as required for sexual relations. The placebo will be omitted on nights that 100mgs is used. Placebo will start within 24-48 hours post-surgery.
- Nightly Sildenafil Arm (Type: EXPERIMENTAL): Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery.
- Combination Therapy Arm (Type: EXPERIMENTAL): Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL), at initial dose of 5 units (0.05ml) will be given; the first 2 injections will be done in the MSKCC urology outpatient clinic (if needed, the investigator can determine appropriate amount of injections for patient training).

Based on this trial design, predict the completion outcome and termination type (if applicable).